SCHEMBL2474355

SCHEMBL2474355

COC(=O)[C@H]1CC[C@H](Oc2ccc(Cl)cn2)CC1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.48
DGAT1 O75907 9/20 0.47
SOAT1 P35610 4/20 0.47
KCNH2 Q12809 4/20 0.47
FPR2 P25090 1/20 0.44
PROKR1 Q8TCW9 1/20 0.44
IP6K1 Q92551 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ACACB O00763 1/20 0.40
NAMPT P43490 1/20 0.39
LIPE Q05469 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2474358 1.00 MMP1 (0.48) MMP1DGAT1SOAT1KCNH2FPR2
SCHEMBL30356854 0.85 DGAT1 (0.43) DGAT1SOAT1KCNH2ACACBNAMPT
SCHEMBL1588120 0.84 DGAT1 (0.43) DGAT1SOAT1KCNH2ACACBNAMPT
SCHEMBL1588552 0.84 DGAT1 (0.52) MMP1DGAT1SOAT1KCNH2SMN1; SMN2
SCHEMBL2472636 0.84 DGAT1 (0.47) DGAT1SOAT1KCNH2ACACBNAMPT
SCHEMBL1588545 0.84 DGAT1 (0.43) DGAT1SOAT1KCNH2ACACBNAMPT
SCHEMBL1588553 0.84 DGAT1 (0.52) MMP1DGAT1SOAT1KCNH2SMN1; SMN2
SCHEMBL1588118 0.84 DGAT1 (0.43) DGAT1SOAT1KCNH2ACACBNAMPT
SCHEMBL2472635 0.84 DGAT1 (0.47) DGAT1SOAT1KCNH2ACACBNAMPT
SCHEMBL2477556 0.83 MMP1 (0.45) MMP1DGAT1SOAT1KCNH2FPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370441-B1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-09-11 EP disclosed
US-8461152-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2013-06-11 US disclosed
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES SCHNIDER PATRICK (CH) 2012-09-06 US disclosed
US-8227458-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
EP-2370441-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-10-05 EP disclosed
WO-2010060836-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-03 WO disclosed
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES HOFFMANN-LA ROCHE, INC. 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 MMP1 2983/4885DGAT1 2921/4885SOAT1 2985/4885
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 MMP1 2983/4885DGAT1 2921/4885SOAT1 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.